{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:58:00Z","timestamp":1792598280469,"version":"4.5.0"},"reference-count":0,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neonatology"],"published-print":{"date-parts":[[2024]]},"abstract":"<b><i>Introduction:<\/i><\/b> There is no consensus regarding the efficacy of add-on therapy with levetiracetam (LEV) in the treatment of seizures in neonates. The aim of this study was to evaluate the efficacy of add-on therapy with LEV for achieving &gt;80% seizure reduction after phenobarbital (PB) treatment. <b><i>Methods:<\/i><\/b> Retrospective cohort study of near term neonates admitted to the neonatal intensive care unit with EEG-confirmed seizures despite treatment with PB as first-line therapy and using LEV as 2nd-, 3rd- or 4th-line treatment. Antiseizure medication was administered according to national guidelines. All neonates were monitored with 2-channel amplitude-integrated electroencephalography. The total seizure burden in minutes, 2 h before and 4 h after administration of LEV, was calculated using raw EEG. Primary outcome was the efficacy of LEV in achieving &gt;80% seizure reduction. The efficacy of additional midazolam (MDZ) and lidocaine (LDC) was also calculated. <b><i>Results:<\/i><\/b> A total of 47 full-term neonates were included. The mean total loading dose of LEV was 40 mg\/kg (36\u201344 mg\/kg). Seizure etiology consisted of hypoxic-ischemic encephalopathy (<i>n<\/i> = 11), hemorrhagic or ischemic stroke (<i>n<\/i> = 16), central nervous system infection (<i>n<\/i> = 8), genetic (<i>n<\/i> = 8), metabolic disorders (<i>n<\/i> = 3), and unknown (<i>n<\/i> = 1). Following LEV administration, &gt;80% seizure reduction was observed in 17% (8\/47) of neonates, whereas it was 23% (6\/26) after MDZ and 92% (23\/25) after LDC administration. <b><i>Discussion:<\/i><\/b> Although the cumulative loading dose of LEV was low and the group of infants studied was heterogeneous, the efficacy of LEV as add-on therapy for the treatment of seizures in neonates was limited. The highest seizure reduction rate was seen after LDC administration. <\/jats:p>","DOI":"10.1159\/000535499","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T14:53:57Z","timestamp":1703084037000},"page":"233-243","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of Levetiracetam as Add-On Therapy in the Treatment of Seizures in Neonates"],"prefix":"10.1159","volume":"121","author":[{"given":"Mathies","family":"Rondagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"De Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cacha M.P.C.D.","family":"Peeters-Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma C.","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylke. J.","family":"Steggerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2023,12,19]]},"container-title":["Neonatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/neo\/article-pdf\/121\/2\/233\/4188734\/000535499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/neo\/article-pdf\/121\/2\/233\/4188734\/000535499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:58:05Z","timestamp":1745423885000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000535499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,2]]},"published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1159\/000535499","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.24805728","asserted-by":"subject"}]},"ISSN":["1661-7800","1661-7819"],"issn-type":[{"value":"1661-7800","type":"print"},{"value":"1661-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]}}}